Biotest (BIO) AI Stock Analysis

• Market Cap: €1.38B
• Dividend Yield: 0.1%
• Average Volume (3M): 46.00
• Price to Earnings (P/E): 64.1
• Beta (1Y): -0.12
• Revenue Growth: -18.82%
• EPS Growth: -113.85%
• Country: DE
• Employees: 2,495
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 19,785,727
• 10 Day Avg. Volume: 27
• 30 Day Avg. Volume: 46
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €41.00
• Price Target Upside: 2.50% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 55 Neutral
• Price Target: €41.00 ▲(2.50% Upside)

Biotest's overall stock score is primarily influenced by its balanced financial performance and stable cash flows, despite challenges in profitability and operational efficiency. The technical analysis indicates a neutral market outlook, while the valuation is weighed down by a negative P/E ratio, offset slightly by a high dividend yield.

Biotest Business Overview & Revenue Model

Company Description

Biotest AG is a global biotechnology company headquartered in Germany, specializing in the development, production, and marketing of immunology and hematology products. The company focuses on therapies derived from human blood plasma, particularly for treating immune deficiencies, hemophilia, and other blood-related disorders. Key products include immunoglobulins, clotting factors, and albumin, which are essential for various medical treatments.

How the Company Makes Money

Biotest generates revenue primarily through the sale of its plasma-derived products, which are marketed to hospitals, clinics, and specialty distributors worldwide. The company has established a robust revenue model centered around the collection and processing of human plasma, which is critical for its product lines. Key revenue streams include sales from immunoglobulin products, albumin, and clotting factor therapies. Additionally, Biotest benefits from partnerships with healthcare providers and institutions, which enhance its distribution capabilities and market reach. The company may also engage in collaborations and research agreements that could provide additional funding and support for its product development initiatives.

Biotest Financial Statement Overview

Summary

Biotest shows balanced financial performance with a stable balance sheet and improved cash flows. However, there are challenges in maintaining consistent profitability due to operational inefficiencies.

Income Statement

Biotest's income statement shows a mixed performance. Gross Profit Margin improved to 30.82% in the latest year, coupled with a positive Net Profit Margin of 3.63%, indicating moderate profitability. However, the company experienced a significant drop in Gross Profit from the previous year, suggesting volatility in profit generation. Revenue growth from 2023 to 2024 was 6.08%, which is positive but marked by a decline in EBIT and EBITDA margins, indicating rising operational costs or inefficiencies.

Balance Sheet

The balance sheet of Biotest indicates a stable financial position. The Debt-to-Equity Ratio stands at 1.13, reflecting a balanced capital structure. Return on Equity is modest at 4.97%, showing moderate returns to equity holders. The Equity Ratio of 37.00% suggests a strong equity base relative to total assets, enhancing financial stability. However, the increase in total debt over time could pose potential risks if not managed well.

Cash Flow

Biotest's cash flow statements reveal stable cash flow management. Operating Cash Flow to Net Income Ratio is 2.31, indicating strong cash generation relative to net income. Free Cash Flow improved significantly to a positive $32.2 million in 2024 from a negative position in the prior year, suggesting robust cash flow improvement. However, the fluctuation in free cash flow growth over the years denotes potential instability in cash generation capability.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	726.20M	684.60M	516.10M	515.60M	484.20M
Gross Profit	223.80M	280.30M	124.90M	80.70M	130.10M
EBITDA	120.40M	179.00M	28.30M	-17.70M	16.00M
Net Income	26.40M	127.00M	-31.60M	-63.30M	-31.40M
Balance Sheet
Total Assets	1.43B	1.41B	1.20B	1.10B	1.13B
Cash, Cash Equivalents and Short-Term Investments	119.50M	118.50M	136.60M	117.50M	89.20M
Total Debt	597.20M	689.80M	574.30M	496.30M	469.10M
Total Liabilities	903.30M	912.00M	831.90M	723.80M	689.70M
Stockholders Equity	530.70M	498.90M	371.10M	380.40M	441.60M
Cash Flow
Free Cash Flow	32.20M	-36.10M	-69.80M	15.70M	-43.70M
Operating Cash Flow	60.90M	-2.70M	-40.50M	33.90M	-16.70M
Investing Cash Flow	-25.70M	1.30M	-37.00M	-23.40M	-14.60M
Financing Cash Flow	-35.40M	-6.80M	89.60M	22.60M	42.00M

Biotest Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 40.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BIO, the sentiment is Negative. The current price of 40 is below the 20-day moving average (MA) of 40.80, below the 50-day MA of 41.24, and below the 200-day MA of 41.56, indicating a bearish trend. The MACD of -0.34 indicates Positive momentum. The RSI at 45.27 is Neutral, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:BIO.

Biotest Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ILM1	75 Outperform	$361.16M	19.48	3.56%	―	7.02%	10.58%
Sector *	62 Neutral	€5.97B	17.37	-3.61%	2.14%	0.53%	-36.19%
EUZ	58 Neutral	€1.13B	30.56	17.61%	2.86%	9.42%	9.54%
FYB	57 Neutral	€440.81M	5.89	-34.48%	―	-14.84%	-338.52%
BIO	55 Neutral	€1.38B	64.15	-4.72%	0.10%	-18.82%	-113.85%
EVT	44 Neutral	€1.09B	―	-16.75%	―	-1.41%	9.05%